中文
About Us
Corporate Overview
Management Team
Board of Directors
Contact Us
Our Focus
Metabolic Diseases
Immune Diseases
Exploratory Indications
Pipeline
Pipeline
Clinical Trials
Partnership
Investors
Financials & Filing
Upcoming Events
Corporate presentation
SCIENTIFIC PRESENTATIONS
News
Careers
Investors
Financials & Filing
Upcoming Events
Corporate presentation
SCIENTIFIC PRESENTATIONS
2026
2025
2024
2023
2022
2021
2020
2019
2018
2026
2025
2024
2023
2022
2021
2020
2019
2018
Voluntary Announcement - Ascletis Highlights Oral and Long-Acting Injectable Anti-Obesity Preclinical Studies at ObesityWeek® 2026
2026-11-16
Voluntary Announcement - Ascletis Submits IND Application to the U.S. FDA for ASC30_39 FDC, a Potentially First-in-Class Oral Small Molecule Fixed-Dose Combination of GLP-1R Agonist and Selective Amylin Receptor Agonist, for the Treatment of Obesity
2026-11-11
Next Day Disclosure Returns - Share Buyback
2026-11-06
Next Day Disclosure Returns - Share Buyback
2026-11-05
Grant of Share Options
2026-11-04
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
2026-11-04
Voluntary Announcement - Ascletis to Present Study Results of Oral Small Molecule GIPR Agonist ASC48 and GLP-1R/GIPR/GCGR Triple Peptide Agonist ASC37 at Obesityweek® 2026
2026-11-02
Next Day Disclosure Returns - Share Buyback
2026-10-30
Next Day Disclosure Returns - Share Buyback
2026-10-29
Voluntary Announcement - Ascletis’ Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted HbA1c Reduction of 1.7% at 12 Weeks from Its U.S. Phase II Study in Participants with Diabetes
2026-10-29
1
2
3
4
»